LAUPHEIM, Germany & MUNICH/MARTINSRIED, Germany--(BUSINESS WIRE)--Rentschler Biopharma SE and Leukocare AG today reported on the successful first year of their unique strategic alliance. The collaboration incorporates best-in-class formulation development in every step of the biopharmaceutical development and manufacturing process. The benefits of this combination include competitive advantages, shorter development timelines, cost savings and extra patent protection for client products. The entire manufacturing process can be made more effective. In the past year, the alliance has won several new client projects, including four with US-based companies.
Dr. Frank Mathias, CEO of Rentschler Biopharma SE, commented: "The first year of this strategic alliance between Rentschler Biopharma and Leukocare was a great success and has proven our rationale to deliver best-in-class formulation throughout the biopharmaceutical value chain. By repositioning formulation as a key success factor in biopharmaceutical development, we have initiated vital discussions throughout the industry. Both existing and new clients have responded very positively to this new strategy."
"Over the past year, our alliance has received a great deal of interest and recognition for this striking approach," stated Michael Scholl, CEO of Leukocare AG. "We have been able to expand our client base, particularly in the US, and look forward to acquiring further clients and development projects in the near term. This innovative approach provides our current and future clients significant competitive advantages, enabling them to exploit the full potential of their products and markets."
Leukocare is the specialized technology partner and the exclusive formulation developer for Rentschler Biopharma's biopharmaceutical development business. Rentschler Biopharma is the first and only CDMO to have access to Leukocare's patented SPS(R) formulation technologies. As part of the original agreement, Rentschler Biopharma holds a 10% stake in Leukocare and Dr. Frank Mathias is a member of Leukocare's Board of Directors.
About Rentschler Biopharma SE
Rentschler Biopharma SE,
located in Laupheim, Germany, is a leading contract development and
manufacturing organization (CDMO) for bioprocess development and
manufacturing of biopharmaceuticals as well as for related consulting
activities in terms of project management and regulatory support. The
Company's clients include innovative biotech companies and major
pharmaceutical companies around the world. Many years of experience and
excellence in finding solutions as well as certified quality management
and advanced technologies ensure Rentschler Biopharma's high quality
standards. Rentschler Biopharma is a family-owned company employing
approximately 800 people. For further information, please visit www.rentschler-biopharma.com.
About LEUKOCARE AG
LEUKOCARE AG, located in Martinsried,
Germany, provides a next-generation formulation platform for the
protection of proteins like biopharmaceuticals to allow the development
of better products. The proprietary SPS(R) technologies are provided to
development projects of partners in the pharmaceutical and medical
device industry. LEUKOCARE's SPS(R) technologies improve stability and
quality of biologics like antibodies, vaccines, etc. in dry and liquid
formulation. SPS(R) also protects proteins in biologically
functionalized combination devices. For further information, please
visit www.leukocare.com.
About the Rentschler Biopharma and Leukocare alliance
The
alliance between Rentschler Biopharma SE and Leukocare AG strategically
aims to incorporate formulation development at every step throughout
biopharmaceutical development and manufacturing. Working closely with
the client, this will ensure that the end products will - from the very
beginning - have a best-in-class formulation and administration mode.
This innovative approach will provide clients significant competitive
advantages, enabling them to exploit the full potential of their
products and markets.